![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
TR Insel, G Battaglia, JN Johannessen, S Marra and EB De Souza
Laboratory of Clinical Science, National Institute of Mental Health, Poolesville, Maryland.
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"), an amphetamine analog, is a "designer drug" which is being increasingly abused. The potential neurotoxic hazard of MDMA in humans was assessed by examining the effects of repeated systemic administration of MDMA on selected neurochemical and behavioral measures in rhesus monkeys. In the first study, MDMA (2.5 or 10 mg/kg twice daily for 4 days) produced selective and significant neurochemical decreases in cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA) and brain concentrations of serotonin and 5-HIAA. At the high dose of MDMA, a selective decrease in serotonin uptake sites (reflecting destruction of brain serotonin terminals) was observed. To determine if these changes after high dose MDMA were pharmacologic or truly neurotoxic, in a subsequent study monkeys were treated with MDMA (10 mg/kg twice daily for 4 days) and then monitored for 14 weeks. Throughout this period, CSF 5-HIAA was decreased in MDMA-treated animals but not in saline- injected controls. At the end of this period, significant decreases in the concentration of serotonin, 5-HIAA and serotonin uptake sites were observed in cerebral cortex and striatum but not in hypothalamus or spinal cord. In contrast to these widespread alterations in serotonin markers, comparable noradrenergic and dopaminergic measures in CSF and brain appeared generally unaffected. These data demonstrating potent and selective effects of MDMA on various brain serotonin parameters in rhesus monkeys suggest that the drug may produce similar effects in humans.
This article has been cited by other articles:
|
|
 |
|
  B. B. Quednow, F. Jessen, K.-U. Kuhn, W. Maier, I. Daum, and M. Wagner Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction J Psychopharmacol, May 1, 2006; 20(3): 373 - 384. [Abstract] [PDF]
|
|
|
|
|
|
N. Easton and C. A. Marsden Ecstasy: Are animal data consistent between species and can they translate to humans? J Psychopharmacol, March 1, 2006; 20(2): 194 - 210. [Abstract] [PDF]
|
|
|
|
 |
|
 A. J. Baucum II, K. S. Rau, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein Methamphetamine Increases Dopamine Transporter Higher Molecular Weight Complex Formation via a Dopamine- and Hyperthermia-Associated Mechanism J. Neurosci., March 31, 2004; 24(13): 3436 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Ricaurte, J. Yuan, G. Hatzidimitriou, B. J. Cord, and U. D. McCann Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA ("Ecstasy") Science, September 27, 2002; 297(5590): 2260 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Szabo, U. D. McCann, A. A. Wilson, U. Scheffel, T. Owonikoko, W. B. Mathews, H. T. Ravert, J. Hilton, R. F. Dannals, and G. A. Ricaurte Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions J. Nucl. Med., May 1, 2002; 43(5): 678 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Hansen, E. L. Riddle, V. Sandoval, J. M. Brown, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein Methylenedioxymethamphetamine Decreases Plasmalemmal and Vesicular Dopamine Transport: Mechanisms and Implications for Neurotoxicity J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1093 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Reneman, J. Lavalaye, B. Schmand, F. A. de Wolff, W. van den Brink, G. J. den Heeten, and J. Booij Cortical Serotonin Transporter Density and Verbal Memory in Individuals Who Stopped Using 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy"): Preliminary Findings Arch Gen Psychiatry, October 1, 2001; 58(10): 901 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hatzidimitriou, U. D. McCann, and G. A. Ricaurte Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery J. Neurosci., June 15, 1999; 19(12): 5096 - 5107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. D. McCann, K. A. Lowe, and G. A. Ricaurte REVIEW {blacksquare} : Long-lasting Effects of Recreational Drugs of Abuse on the Central Nervous System Neuroscientist, November 1, 1997; 3(6): 399 - 411. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
